Company announcement - No. 27/2017
Zealand reports royalty revenue for the second quarter of 2017
-
Zealand reports royalty revenue of DKK 9.1 million in Q2 2017
-
The revenue is based on total net sales of of Lyxumia®/Adlyxin(TM) and Suliqua®/Soliqua® 100/33 of DKK 91.4 million in Q2 2017
Copenhagen, July 31, 2017 - Zealand Pharma ("Zealand") reports Q2 2017 royalty revenue from Sanofi`s sales of Lyxumia®/Adlyxin(TM) (lixisenatide) of DKK 5.2 million and from Suliqua®/Soliqua® 100/33 of DKK 3.9 million. Total royalty revenue for H1 2017 amounted to DKK 17.2 million.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand. Zealand licensed the global development and commercialization rights to lixisenatide to Sanofi. Lixisenatide is marketed under the brand name Lyxumia® in over 45 countries and was launched in the United States under the brand name Adlyxin(TM) in January 2017.
Sanofi has also developed a combination of lixisenatide and insulin glargine 100 units/mL (Lantus®), which was launched under the brand name Soliqua®100/33 in the United States in January 2017 and has been approved as Suliqua® in Europe and launched in the Netherlands in the second quarter of 2017.
Soliqua® 100/33 is approved in the United States as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide alone.
Zealand`s Interim report for the first six months of 2017 will be published on August 24 2017 and will contain more information relating to the launch of Soliqua® 100/33.
For further information, please contact:
Britt Meelby Jensen, CEO and President
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
2
Zealand`s first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands.